drugset / Trial / NCT07307469

Compassionate Administration of ZVS101e for Extended Treatment

NCT07307469 ↗

Enrolling by invitation 32 enrolled Chigenovo Co., Ltd
NaSingle-groupOpen-labelTreatment

Summary

To provide treatment options for the control group of subjects who completed the 52-week follow-up of the Phase III clinical trial (Protocol number: ZYA-2024-001) of ZVS101e in subjects with Bietti crystalline corneoretinal dystrophy (BCD).

Timeline

Start
2026-07
Primary completion
2027-01
Completion
2027-07

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject ZVS101e Gene therapy (AAV / viral vector) — Other